Xeloda (capecitabine) NDC 61269-475

NDC codes

FDA NDC Directory

Product NDC (as listed)61269-475Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61269-0475Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61269-475-12	61269047512	120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61269-475-12)Marketed from Apr 30, 1998

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Xeloda
Generic name (nonproprietary): capecitabine
Active ingredients: Capecitabine — 500 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: H2-Pharma, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020896
Marketing start: Apr 30, 1998
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 61269-475_32dd0155-c5cb-49c2-9b74-74f40df22df7SPL ID 32dd0155-c5cb-49c2-9b74-74f40df22df7SPL set ID e702d84d-7162-4751-bf37-d724cc7e45a5RxCUI 200327, 200328, 213292, 213293UNII 6804DJ8Z9U
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N461269047512 followed by a unit qualifier and the quantity

Package 61269-0475-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 5, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patient…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)